Subject: Magnetic Blood Filtration: removing anything from the bloodstream


  • European Health Catapult
  • Life Science Leadership Summit
  • New Grant Awarded
  • International Women in Engineering Day
  • Press Coverage
  • New Job Postings
  • Meet our employee
Plan Going Forward 
Ensuring steady development 
For the last two months we have continued to push forward our product development while further fleshing out our commercialisation strategy. We are still focussing mainly on our IL-6 related products, which are aimed at tackling a broad range of diseases including COVID-19. We are working alongside major companies in the industry and regularly sharing progress with the media. We have attended digital events to meet up with the investors and innovators and joined international campaigns to raise awareness of some of the issues that we care about. This July our team has also joined the London Business Growth Programme which provides business training and networking sessions with other London-based innovators.
MediSieve is a semi-finalist of the European Health Catapult
We were selected as winners of the regional round of the EIT Health Catapult, a training and competition programme that boosts the development of European health start-ups by exposing them to top-quality experts and international investors. This autumn we will be showcasing our technology in front of the leading investors and innovators in order to win a chance to enter the finals in December.
Learn more here:

MediSieve at Life Science Leadership Summit
This June we attended another digital conference - Life Science Leadership Summit organised by BioIndustry Association. We had an opportunity to meet leading industry's investors and and other BIA member CEOs.
Read more:

New Grant Awarded
We have been awarded a COVID-19 Continuity Grant from Innovate UK, which provides extra funding worth £222k for our previously awarded Biomedical Catalyst Grant. This will help mitigate the financial effects of the coronavirus pandemic while enabling us to continue developing our crucial IL-6 removal products with an eye on providing a treatment for severe COVID-19 cases. For the past few months, we have been focusing exclusively on these products in order to respond to the pandemic (severe COVID-19 patients die from IL-6 driven hyperinflammation).
Follow us for more company insights:
International Women in Engineering Day
Toward the end of June we celebrated the International Women in Engineering Day. The campaign aims to highlight the importance of the role that women play in engineering sector and value of gender diversity, to encourage more young women to consider a career in engineering. Our CTO, Cristina Blanco-Andujar, shared her thoughts on the benefits of gender diversity in engineering overall, and how having a diverse team has benefitted MediSieve.
Read more:
MediSieve in the Press
We continue to share our mission and research development with leading media agencies.  Over the last few months, our team has been talking to Imperial News and Engineering & Technology magazines about the impact of the pandemic on our work. We shared news about how our Head of Engineering and Quality, Will Twigger, turned his garage into a workshop, and how we use our technology to tackle COVID-19.
Follow our news here
MediSieve Is Hiring! 
We are once again looking to grow our fantastic team to help us get our exciting blood filtration technology through clinical trials and into the market. We are looking for highly motivated, engaging and proactive people to join our team as Product Development Manager and Simulation Engineer
Learn more about the vacancies and apply here:
MediSieve Faces 
MediSieve is working on creating a novel blood filtration technology that will be the first of its kind. But what truly sets us apart from other companies is our people. Meet the individuals who are transforming our dream of eliminating the burden of blood-borne diseases into reality:
Chris Jones
Strategic Director 
Nationality: American
Joined: October 2015

How did you join MediSieve?
- I first met George when he was developing the magnetic blood filter for his PhD. I was on a phone call with his father David Frodsham, who was running the CEO Collaborative Forum, when he said, “You know something about medical devices and blood, don’t you? Can my son ask you some questions?” I can’t remember what exactly George wanted to know, but I do remember sometime during the ensuing e-mail discussion about applications for the magnetic blood filter, suggesting to George that he needed to decide whether he wanted to save the world or make money. When he replied, “Why can’t I do both?” I decided that I really wanted to be part of this journey. We kept in touch and when George founded MediSieve he asked me to become an investor and a board member and I was happy to do both.

What is your role within the company?
- In addition to my role as a Non-Executive Director, I spend 2-4 days a month in a hands-on role supporting fundraising, grant applications, commercial planning, IP and contract negotiation. My title is Strategic Director, which is purposely ambiguous and allows me to contribute to whichever non-technical business challenge is most pressing at the moment.

What do you like most about working with MediSieve?
- Peter Drucker’s famous quote, “Culture eats strategy for breakfast” often gets overlooked by early stage start-ups in the mad rush of the early days where all attention is on getting to proof of concept. At MediSieve, however, I think it is one of the key elements of success. George and Cristina have built a great team of talented and enthusiastic people working to do something that has never been done before. The combination of energy, enthusiasm and collaboration that has developed as the company grew from 2 people to 12 is what makes working with MediSieve really enjoyable.

How did the COVID-19 outbreak affect your personal and work life?
- I have been very fortunate that with all of the online video calling tools, most of what I do can be done in my home office. My biggest professional concern when it hit was around fundraising, as prior to COVID-19 investors always expected one if not multiple face to face meetings before making an investment. Fortunately it appears the investing world is also adapting to video calls and remote diligence and I was able to close a round in early July for another medtech company.

"Imagine a world where doctors are able to target and remove infected cells, pathogens, toxins, or even viruses directly from a patient’s bloodstream."
You may unsubscribe or change your contact details at any time.